Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial

Gotta, V; Widmer, N; Decosterd, L A; Chalandon, Yves; Heim, D; Gregor, M; Benz, R; Leoncini-Franscini, L; Baerlocher, G M; Duchosal, M A; Csajka, C; Buclin, Thierry

doi:10.1007/s00280-014-2599-1

Scientific article

English

Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial

ContributorsGotta, V; Widmer, N; Decosterd, L A; Chalandon, Yves; Heim, D; Gregor, M; Benz, R; Leoncini-Franscini, L; Baerlocher, G M; Duchosal, M A; Csajka, C; Buclin, Thierry

Published inCancer chemotherapy and pharmacology, vol. 74, no. 6, p. 1307-1319

Publication date2014

Abstract

This study assessed whether a cycle of "routine" therapeutic drug monitoring (TDM) for imatinib dosage individualization, targeting an imatinib trough plasma concentration (C min) of 1,000 ng/ml (tolerance: 750-1,500 ng/ml), could improve clinical outcomes in chronic myelogenous leukemia (CML) patients, compared with TDM use only in case of problems ("rescue" TDM).

Keywords

Adult
Aged
Antineoplastic Agents/administration & dosage/pharmacokinetics/therapeutic use
Benzamides/administration & dosage/pharmacokinetics/therapeutic use
Dose-Response Relationship, Drug
Drug Monitoring/methods
Female
Follow-Up Studies
Humans
Individualized Medicine/methods
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy/pathology
Male
Middle Aged
Piperazines/administration & dosage/pharmacokinetics/therapeutic use
Prospective Studies
Pyrimidines/administration & dosage/pharmacokinetics/therapeutic use
Treatment Outcome

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Groupe Lecompte Thomas Pierre (hématologie) (918)

Citation (ISO format)

GOTTA, V et al. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial. In: Cancer chemotherapy and pharmacology, 2014, vol. 74, n° 6, p. 1307–1319. doi: 10.1007/s00280-014-2599-1

Article (Published version)

Identifiers

PID : unige:55998
DOI : 10.1007/s00280-014-2599-1
PMID : 25297989

Journal ISSN0344-5704

469views

0downloads

Creation01/05/2015 14:48:00

First validation01/05/2015 14:48:00

Update time15/03/2023 00:15:12

Status update15/03/2023 00:15:12

Last indexation19/11/2024 16:02:39

Archive ouverte UNIGE

Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial

Technical informations